ELAB
PMGC Holdings Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.01
P/S
0.12
EV/EBITDA
0.35
DCF Value
$-8,186.76
FCF Yield
-8742.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
31.4%
Operating Margin
-1318.6%
Net Margin
0.0%
ROE
0.0%
ROA
0.0%
ROIC
0.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $304.1K | $4.7M | $397.68 |
| FY 2025 | $590.1K | $0.00 | $0.00 |
| Q3 2025 | $285.9K | $-2.6M | $-117.84 |
| Q2 2025 | $0.00 | $-562.4K | $-37.92 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.12
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.